A phase II open-label study of cabozantinib after first-line treatment including an immune-checkpoint combination in patients with advanced or unresectable renal cell carcinoma: The BREAKPOINT trial (MeetUro trial 03 - EudraCT number 2018-000582-36).

Giuseppe Procopio,Chiara Pircher,Melanie Claps,Valentina Guadalupi,Alessia Mennitto,Pierangela Sepe,Francesca Corti,Ugo De Giorgi,Cristian Lolli,Umberto Basso,Marco Maruzzo,Davide Bimbatti,Elena Verri,Franco Nolè,Sandro Pignata,Filippo de Braud,Elena Verzoni,Meet Uro

A phase II open-label study of cabozantinib after first-line treatment including an immune-checkpoint combination in patients with advanced or unresectable renal cell carcinoma: The BREAKPOINT trial (MeetUro trial 03 - EudraCT number 2018-000582-36).

2021

Giuseppe Procopio
Chiara Pircher
Melanie Claps
Valentina Guadalupi
Alessia Mennitto
Pierangela Sepe
Francesca Corti
Ugo De Giorgi
Cristian Lolli
Umberto Basso
Marco Maruzzo
Davide Bimbatti
Elena Verri
Franco Nolè
Sandro Pignata
Filippo de Braud
Elena Verzoni
Meet Uro

326Background: Antiangiogenic therapy has been a milestone in the treatment of metastatic renal cell carcinoma (mRCC) for years. The positive results with immune-checkpoint inhibitors (ICI) are cha...

Keywords:

Breakpoint
open label study
Oncology
Immune checkpoint
Cabozantinib
Renal cell carcinoma
in patient
first line treatment
Medicine
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations